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The very high mortality rate of glio-mas reflects the unmet therapeutic 
need associated with this type of brain 
tumor. We have discovered that the 
plasma membrane fulfills a critical role in 
the propagation of tumorigenic signals, 
whereby changes in membrane lipid con-
tent can either activate or silence relevant 
pathways. We have designed a synthetic 
fatty acid, 2-hydroxyoleic acid (2OHOA), 
that specifically activates sphingomyelin 
synthase (SGMS), thereby modifying 
the lipid content of cancer cell mem-
branes and restoring lipid levels to those 
found in normal cells. In reverting, the 
structure of the membrane by activat-
ing SGMS, 2OHOA inhibits the RAS-
MAPK pathway, which in turn fails to 
activate the CCND (Cyclin D)-CDK4/
CDK6 and PI3K-AKT1 pathways. The 
overall result in SF767 cancer cells, a 
line that is resistant to apoptosis, is the 
sequential induction of cell cycle arrest, 
cell differentiation and autophagy. Such 
effects are not observed in normal cells 
(MRC-5) and thus, this specific activa-
tion of programmed cell death infers 
greater efficacy and lower toxicity to 
2OHOA than that associated with temo-
zolomide (TMZ), the reference drug for 
the treatment of glioma.
Gliomas are CNS tumors that are resistant 
to apoptosis and that are associated with 
high mortality. The high proliferation 
rate of gliomas and other cancer cells is a 
key (upstream) event in their tumorigenic 
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transformation, which we have shown to 
be associated with very low levels of sphin-
gomyelin (SM) and a high phosphatidyl-
ethanolamine (PE) content in the plasma 
membrane. 2OHOA is a compound that 
specifically activates SGMS, restoring the 
SM and PE levels in cancer cell membranes 
to those found in normal cells. This effect 
on membrane lipid structure changes the 
type of proteins that interact with the 
membrane, and influences other protein-
protein interactions, thereby inducing 
cell cycle arrest, cancer cell differentia-
tion and autophagy. Indeed, inhibiting 
SGMS in part reverses the antiprolifera-
tive effects of 2OHOA, demonstrating 
the specificity of this effect. By contrast, 
2OHOA does not alter the lipid profile 
of normal cells, in which the relatively 
high levels of SM, the product of SGMS, 
and the low levels of PE, the substrate of 
SGMS, maintain the activity of SGMS at 
a low level. This regulatory influence on 
the lipid composition of the glioma cell 
membrane causes RAS to translocate to 
the cytoplasm and the inactivation of the 
MAPK pathway, as well as PRKC/PKC 
translocation to the membrane associated 
with the concomitant induction of the 
CDK inhibitors, CDKN1A/p21Cip1 and 
CDKN1B/p27Kip1. As a result, the forma-
tion of CCND-CDK4/CDK6 complexes 
is impaired causing hypophosphoryla-
tion of the retinoblastoma protein (RB1/
pRb), E2F1 inhibition and knockdown 
of DHFR. In addition, 2OHOA pro-
vokes the inhibition of the PI3K-AKT1 
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A number of conclusions can be drawn 
from our studies. First, low SM and high 
PE levels in the plasma membrane appear 
to be necessary to induce cancer cell pro-
liferation, along with oncogene activa-
tion and tumor suppressor inactivation, 
representing the third basic requirement 
for the expression of a malignant pheno-
type. Moreover, the structural status of 
the membrane appears to lie upstream of 
the activation of certain oncogenes (e.g., 
RAS), therefore being a cellular switch for 
cell proliferation. Thus, normalization of 
the membrane lipid composition/struc-
ture by 2OHOA induces cell cycle exit 
and initiation of a program of autophagy. 
Indeed, when glioma (SF767) cells stop 
proliferating and start differentiating, the 
program of autophagy (or other programs 
of cell death) commences. Micrographs 
showing the presence of autophagosomes, 
dramatic cell fragmentation and the 
appearance of the autophagosome marker 
LC3B along with ATG5, clearly indicate 
the relatively late (time and concentration 
dependent) onset of autophagy in glioma 
cells. Second, we have defined SGMS as 
a new anticancer drug target for which 
2OHOA is a first-in-class SGMS activator. 
Third, 2OHOA clearly induces glioma 
cell differentiation. The greater efficacy 
and lack of tumor relapse after 2OHOA 
administration with respect to TMZ 
(the reference drug for the treatment of 
induce a molecular conflict that triggers 
cancer cell death. From the molecular 
point of view, this conflict could be pro-
duced when cells such as SF767 glioma 
cells accumulate high levels of CDKN1B, 
hypophosphorylated RB1, and when 
AKT1 is inhibited and FOXO1 acti-
vated, precisely the conditions promoted 
by 2OHOA (Fig. 1). Interestingly, auto-
phagy appears to be delayed with respect 
to cell cycle arrest and the induction 
of differentiation. Indeed, significant 
increases in the appearance of the mark-
ers of autophagy, LC3B and ATG5 were 
only observed 72 h after treatment with 
2OHOA. Accordingly, it appears that 
the regulatory scenario imposed by the 
membrane structure is incompatible with 
the mutations present in many cancer 
cell lines. Finally, we have seen that the 
specific cell death induced by 2OHOA 
in glioma cells is associated with ER 
stress and sphingolipidosis caused by an 
increase in SM and concomitant altera-
tions in sphingolipid metabolism. These 
phenomena could be directly related to 
cancer cell death and they could cause 
autophagy or other types of programmed 
cell death (e.g., apoptosis) observed in 
other types of cancer cells. In addition, 
sphingolipidosis/ER stress could cause 
the various morphological/cellular altera-
tions observed upon 2OHOA treatments 
in cancer cells.
pathway, probably due to crosstalk with 
the receptor tyrosine kinase (RTK)-RAS-
MAPK pathway (Fig. 1).
In light of these data, the membrane 
lipid composition appears to be critical 
for the increased proliferation, loss of dif-
ferentiation and the evasion of cell death 
that is typical of tumor cells, and it offers 
a molecular explanation for the mode of 
action of 2OHOA in combating cancer. 
We have shown how membrane lipids reg-
ulate the binding of peripheral signaling 
proteins and protein-protein interactions 
at the membrane, defining microdomains 
with distinct affinities for specific pro-
teins. Accordingly, RAS is preferentially 
bound to the membrane of many cancer 
cells, while in normal cells and follow-
ing exposure of cancer cells to 2OHOA, 
it preferentially accumulates in the cyto-
plasm. Since the presence of RAS at the 
membrane is necessary to propagate sig-
nals from RTKs to RAF, the detachment 
of RAS from the membrane inactivates 
the MAPK pathway (Fig. 1).
The first event induced by 2OHOA 
is cell cycle arrest (initiated within 24 h 
of exposure), later also inducing glioma 
cell differentiation (ca. 48–72 h). Cancer 
cells are characterized by rapid growth, as 
well as their dissemination and the inva-
sion of other tissues. In this context, the 
changes caused by 2OHOA in glioma cell 
proliferation and differentiation possibly 
Figure 1. the induction of autophagy in glioma cells treated with 2OhOA. the illustration on the left depicts the membrane structure and the active 
(black) or inactive (red) cell signals in glioma cells. high pE and low Sm levels favor the activation of the mApK pathway, which in turn induces the activ-
ity of the cyclin-cDK and pi3K pathways. the illustration on the right depicts the membrane lipid status in 2OhOA-treated cells, with more Sm and less 
pE than untreated glioma cells, which causes the uncoupling of RAS and the concomitant inactivation of the mApK and related pathways. Activation 
of FOXO1, overexpression of cDKn1B, hypophosphorylation of RB1 and inactivation of AKt1, contributes to the molecular scenario associated with 
the activation of autophagy in glioma but not normal cells. in this context, the membrane lipid structure appears to be the most upstream event that 
controls cell proliferation, differentiation and autophagy in glioma cells, SgmS thereby representing a new target for anticancer therapies.
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glioma) constitutes proof-of-relevance 
and demonstrates the great potential of 
the specific induction of autophagy to 
combat cancer. Normal cells already have 
high levels of SM, and 2OHOA does not 
induce a further rise in the membrane SM 
content and the ensuing events observed 
in cancer cells, including autophagic cell 
death. Hence, the IC
50
 of 2OHOA in nor-
mal human embryonic cells is about 100-
fold greater than that observed in cancer 
cells. This very high specificity for cancer 
cells is associated with the absence of side 
effects associated with 2OHOA.
